发功剂量与疗效的曲线形状:治疗师特质如何决定”几成功力

Written by

in

Language

Evidence level: B

治疗师特质(修为年限+发功状态标志+量表)与疗效之间,很可能不是”功力越深效果越好”的直线,而是一条有形状、有拐点、有阈值的曲线——而这条曲线的形状本身,就是可以检验的科学假设。

正文

上一轮我们论证了外气疗效的”治疗师效应”可以被分解为可测变量:发功状态的 HRV/EEG 生理标志、治疗师特质(修为年限、自评能力、标准化量表)、以及治疗剂量。但”可测”不等于”可预测”。一个更尖锐的问题是:把这些变量当作剂量输入、疗效当作反应输出,两者之间到底是什么形状的函数关系? 线性(每多一年修为,疗效稳定增加)?饱和(功力到一定程度后,再多也没用)?还是有阈值(不到某个水平根本不显效,过了才起飞)?这个问题直接决定两件现实的事:外气研究该招募什么样的治疗师、以及”练到什么时候才够格上临床”。

从心理治疗借来的”剂量-反应曲线”是现成的参照系。 心理治疗领域早就回答过类似的问题。Howard 等人 1986 年用概率模型分析 2400 多名患者的 15 组数据,得出著名的”剂量-效应”曲线:治疗 8 次时约 50% 的患者出现可测改善,26 次时约 75%(PMID 3516036);这一曲线后来被多次实证复现,且治疗师层变量的作用成为现代研究重点(PMID 27424106)。这条曲线的关键形状是”负加速”——前几次收益最大,之后边际收益递减。后续研究进一步发现,患者结局差异中约 5.8% 可归因于治疗师本人,且治疗师胜任力与剂量交互决定结局:边缘型人格障碍 CBT 试验中,”足量+高胜任治疗师”组患者自杀行为减少的效应量比粗估高 2-3 倍(PMID 27424106)。这给外气研究最大的启示不是”曲线是负加速”,而是:治疗师变量既不能忽略、也不能只当协变量——它可能与剂量交互,改变曲线形状。

生物场疗法自己已经露出了剂量-反应形状的苗头,只是没人去拟合曲线。 一项纳 28 项 RCT(1775 名受试者)的非接触生物场疗法综述发现,18 项高质量试验中 12 项报告至少一个主要结局显著获益,同时指出各试验在次数、时长、对照设计上高度异质,无法合并估计剂量(PMID 25181286)。另一项 Reiki 的 14 项随机安慰剂对照试验综述更有意思:它把”治疗师训练水平与经验”当作独立变量来审——使用 1-2 级(低层级)且经验不足 3 年的治疗师的研究没有显著结局,而几乎所有使用 Reiki Master(大师级)的研究都出现显著差异;经验 4 年以上的大师级或 2 级治疗师被建议作为研究底线(PMID 35911042)。这几乎就是一个”阈值型”曲线的雏形:治疗师特质低于门槛时疗效不显著,跨过门槛后差异才出现。 这比”经验越多越好”的直线假说更精确,也更接近修炼传统的直觉——”传度””灌顶””出师”本质上就是在划门槛。

气功侧的对照实验也提供了方向性证据。 一项用”假大师”做安慰剂对照的复杂区域疼痛综合征试验里,真气功组 82% 的患者第一次治疗后报告疼痛减轻,对照组只有 45%;疗程末真组 91% 报告镇痛,对照组 36%(PMID 9893315)。关键在两组的指导内容几乎一样,唯一差别是发功者的”真/假”身份——治疗师特质的作用被隔离出来了。另一项纤维肌痛试验用 5-7 次外气治疗,触痛点计数从 136.6 降到 59.5、FIQ 从 70.1 降到 37.3,3 个月随访基本保持(PMID 17109575)。这些数据没直接画曲线,但共同指向:治疗师特质是真实可操作的自变量,而非不可测的玄学。

那么”曲线形状判定”具体怎么做?核心是一个多治疗师、多中心、盲法的剂量-反应建模:治疗师层采集三组特质变量(修为年限与训练层级、发功状态生理标志——HRV 频域/RMSSD/EEG 相干、标准化特质量表),患者层采集单次疗效结局,对”特质复合得分→疗效”拟合比较四种曲线形状:线性、饱和(负加速)、阈值(门槛以下平坦、以上上升)、线性与阈值混合,用信息准则与 ΔAUC 判定最优形状。判定结果各有含义:线性→”功力即疗效”;饱和→存在边际收益递减,临床只需”够用的治疗师”;阈值→存在”出师门槛”,低于门槛者不应入组,直接为招募标准提供依据。

为什么这个设计特别值得做?它能把外气研究从”又一个阴阳二分结果”推进到”机制与剂量学的定量层面”。心理治疗已证明:曲线形状有政策含义——决定疗程定几次、要不要按治疗师绩效分层(PMID 27424106)。外气若想进入严肃的补充医学证据体系,就必须回答同样的问题:什么水平的治疗师、多少剂量的发功、对应多大的疗效增量——而不是停留在”有没有效”的拉锯战。

当然,障碍同样真实。其一,治疗师特质数据在文献里系统性缺失——多数 RCT 只报”治疗师为某某大师”或干脆不报(PMID 25181286、PMID 35911042 都点名了这一缺口)。其二,”发功状态”标志跨传统不一致(唤醒型 vs 放松型并存),复合得分如何归一仍无共识。其三,若曲线形状因传统而异,需按传统分层建模,样本量需求将成倍上升。

证据与局限

已验证: 心理治疗领域存在负加速的剂量-反应曲线,且治疗师层变量占结局方差约 5.8%、与剂量交互(PMID 27424106);生物场疗法中治疗师层级/经验与结局显著性的关联有初步证据(低层级+<3 年无显著效应 vs 大师级普遍显著,PMID 35911042);”假大师”对照实验显示治疗师身份本身产生镇痛差异(PMID 9893315);外气治疗慢性疼痛有中等质量阳性证据(PMID 17109575)。

部分验证: 非接触生物场疗法 RCT 质量整体偏低、剂量参数异质(PMID 25181286);治疗师特质量表+生理标志的复合得分尚未与疗效结局正式拟合过曲线。

待验证: “特质得分→疗效”曲线的具体形状(线性/饱和/阈值)与拐点位置;曲线形状是否跨传统稳定;同一治疗师特质得分对多次疗效的预测稳定性(特质预测力 vs 状态波动)。

相关阅读

证据等级: B(科学类比/间接证据:心理治疗剂量-反应曲线与治疗师层级-结局关联均有直接实证支撑,但”外气治疗师特质→疗效曲线形状”本身尚无直接检验,本文核心为实验设计方案)
参考文献: PMID 3516036, PMID 27424106, PMID 35911042, PMID 25181286, PMID 9893315, PMID 17109575


免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。

The Curve Shape of Dosage and Efficacy: How Therapist Traits Determine \”How Much Power\

Evidence level: B

There is likely not a linear relationship where “greater cultivation always equals better results,” but rather a shaped curve with inflection points and thresholds between therapist characteristics (years of practice + physiological markers of emission state + standardized scales) and efficacy. The shape of this curve itself constitutes a testable scientific hypothesis.

Main Text

In the previous round, we argued that the “therapist effect” of external qi efficacy can be decomposed into measurable variables: physiological markers of the emission state (HRV/EEG), therapist characteristics (years of practice, self-rated ability, standardized scales), and treatment dosage. However, “measurable” does not equal “predictable.” A sharper question is: What functional relationship exists between treating these variables as dose inputs and efficacy as the response output? Is it linear (stable increase in efficacy per additional year of practice)? Saturating (no further benefit once a certain level is reached)? Or threshold-based (no effect below a certain level, then a sharp rise)? This question directly determines two practical realities: what type of therapist external qi research should recruit, and “at what stage is one qualified for clinical practice.”

The “dose-response curve” borrowed from psychotherapy serves as a ready-made reference frame. The field of psychotherapy has already addressed similar questions. Howard et al. (1986) analyzed 15 datasets from over 2,400 patients using a probabilistic model, deriving the famous “dose-effect” curve: approximately 50% of patients showed measurable improvement after 8 sessions, and about 75% after 26 sessions (PMID 3516036). This curve has been empirically replicated multiple times, and the role of therapist-level variables has become a focal point in modern research (PMID 27424106). The key shape of this curve is “negative acceleration”—maximum gains in the initial sessions, followed by diminishing marginal returns. Subsequent research further found that approximately 5.8% of outcome variance is attributable to the therapist themselves, and therapist competence interacts with dosage to determine outcomes: in a CBT trial for borderline personality disorder, the effect size for reduced suicidal behavior in the “sufficient dose + high-competence therapist” group was 2–3 times higher than crude estimates (PMID 27424106). The greatest insight for external qi research is not that “the curve is negatively accelerated,” but rather: Therapist variables cannot be ignored nor treated merely as covariates—they may interact with dosage to alter the curve’s shape.

Biofield therapies themselves have already revealed the outline of a dose-response relationship, though no one has fitted the curve. A systematic review of 28 RCTs (1,775 participants) in non-contact biofield therapies found that while 12 of the 18 high-quality trials reported significant benefit on at least one primary outcome, it also noted high heterogeneity across trials in frequency, duration, and control design, preventing pooled dose estimation (PMID 25181286). Another systematic review of 14 randomized placebo-controlled trials in Reiki is particularly interesting: it treated “therapist training level and experience” as an independent variable. Studies using Level 1–2 therapists with less than 3 years of experience showed no significant outcomes, whereas almost all studies using Reiki Masters showed significant differences; Masters with over 4 years of experience or Level 2 therapists were recommended as a research baseline (PMID 35911042). This almost constitutes the prototype of a “threshold-type” curve: No significant efficacy below the threshold, but differences emerge once the threshold is crossed. This is more precise than the linear hypothesis that “more experience is always better,” and closer to the intuition of cultivation traditions—”transmission degrees,” “baptisms,” and “graduation” are essentially acts of drawing thresholds.

Control experiments from the Qigong side also provide directional evidence. In a complex trial for regional pain syndrome using “fake masters” as placebo controls, 82% of patients in the True Qigong group reported pain reduction after the first treatment compared to 45% in the control group; at the end of the course, 91% of the True group reported analgesia versus 36% in the control group (PMID 9893315). The critical factor was that the instructional content was nearly identical for both groups; the only difference was the “true/false” identity of the emitter—thereby isolating the effect of therapist characteristics. Another fibromyalgia trial using 5–7 sessions of external qi treatment showed a reduction in tender point counts from 136.6 to 59.5 and FIQ scores from 70.1 to 37.3, with stability maintained at the 3-month follow-up (PMID 17109575). While these data do not directly plot a curve, they jointly point to: Therapist characteristics are real, manipulable independent variables, not unmeasurable metaphysics.

So, how specifically is “curve shape determination” conducted? The core is a multi-therapist, multi-center, blinded dose-response modeling: collect three sets of therapist-level trait variables (years of practice and training level, physiological markers of emission state—HRV frequency domain/RMSSD/EEG coherence, standardized trait scales); collect single-session efficacy outcomes at the patient level; fit and compare four curve shapes (“trait composite score → efficacy”): linear, saturating (negative acceleration), threshold (flat below threshold, rising above), and a mix of linear and threshold. Optimal shape is determined using information criteria and ΔAUC. Each result carries specific implications: Linear → “cultivation equals efficacy”; Saturating → diminishing marginal returns exist, clinical practice only requires “sufficient” therapists; Threshold → a “graduation threshold” exists, those below should not be enrolled, directly providing basis for recruitment criteria.

Why is this design particularly valuable? It can advance external qi research from “another Yin-Yang binary result” to a “quantitative level of mechanism and dosimetry.” Psychotherapy has already demonstrated that curve shape carries policy implications—determining the number of sessions required and whether stratification by therapist performance is needed (PMID 27424106). If external qi wishes to enter a serious supplementary medicine evidence system, it must answer the same question: What level of therapist, what dosage of emission, corresponds to what magnitude of efficacy increment—rather than remaining stuck in a tug-of-war over “whether it works.”

Of course, obstacles are equally real. First, therapist characteristic data is systematically missing in the literature—most RCTs only report “the therapist was Master X” or omit it entirely (PMID 25181286, PMID 35911042 both highlight this gap). Second, markers of “emission state” are inconsistent across traditions (awakening-type vs. relaxation-type coexist), and normalization of composite scores lacks consensus. Third, if curve shape varies by tradition, stratified modeling is required, which will exponentially increase sample size requirements.

Evidence and Limitations

Verified: A negatively accelerated dose-response curve exists in psychotherapy, with therapist-level variables accounting for ~5.8% of outcome variance and interacting with dosage (PMID 27424106); preliminary evidence links therapist hierarchy/experience to outcome significance in biofield therapies (no significant effect for low-level + <3 years vs. universal significance for Masters, PMID 35911042); “fake master” control experiments show that therapist identity itself produces analgesic differences (PMID 9893315); external qi treatment of chronic pain has moderate-quality positive evidence (PMID 17109575).

Partially Verified: Overall RCT quality in non-contact biofield therapies is low, and dosage parameters are heterogeneous (PMID 25181286); composite scores of therapist trait scales and physiological markers have not yet been formally fitted to efficacy outcomes in curve analysis.

To be Verified: The specific shape (“trait score → efficacy”) of the curve (linear/saturating/threshold) and inflection points; whether curve shape is stable across traditions; prediction stability of the same therapist trait score across multiple efficacy instances (trait predictive power vs. state fluctuation).

Related Reading

Evidence Level: B (Scientific Analogy/Indirect Evidence: Direct empirical support exists for psychotherapy dose-response curves and therapist-level-outcome associations, but “external qi therapist traits → efficacy curve shape” itself has not been directly tested; this paper focuses on the experimental design).
References: PMID 3516036, PMID 27424106, PMID 35911042, PMID 25181286, PMID 9893315, PMID 17109575


Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *